V. A. Burmina

V. A. Burmina

Auto-generated profile, based on publicly available information

V. A. Burmina

Federal State Budgetary Educational Institution of Higher Education "Ryazan State Medical University named after Academician I.P. Pavlov" of the Ministry of Health of the Russian Federation, Ryazan, Russian Federation

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2026 in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
Verified
Journal Article
Closed access
SAS. B. Aksentiev
S. B. Aksentiev
OEO. V. Evdokimova
O. V. Evdokimova
NKN. N. Kiryukhinа
N. N. Kiryukhinа
YTYu. D. Tsybakova
Yu. D. Tsybakova
VGV. A. Gencheva
V. A. Gencheva
VBV. A. Burmina
V. A. Burmina
The development of reperfusion methods for the treatment of cerebral infarction, the emergence of new drugs for thrombolytic therapy, and the expansion of indications for reperfusion require a comparative analysis of the effectiveness and safety of various therapeutic methods to achieve optimal treatment tactics and improve the prognosis. The purpose of this study was to evaluate the efficacy and safety of various reperfusion therapy methods in patients with ischemic stroke. The clinical records of 98 patients with ischemic stroke in the middle cerebral artery system were analyzed for clinical and neuroimaging parameters. Patients were divided into groups based on the type of reperfusion therapy and short-term outcome. The nonparametric Mann-Whitney U test was used to assess statistical differences between parameters in the different groups; differences were considered significant at p < 0.05. Different methods of reperfusion therapy showed no significant differences in clinical criteria, with the exception of the volume of ischemic damage. Patients who received thrombolytic therapy with non-immunogenic staphylokinase (Fortelyzin) demonstrated high efficacy rates with a low incidence of hemorrhagic transformation. Prognostically significant factors included the severity and degree of regression of neurological deficit, level of consciousness, and the extent of ischemic brain damage. Hemorrhagic transformation of the ischemic focus is associated with higher mortality but the type of the hemorrhagic transformation influences the prognoses of the survivors.